Quince Therapeutics, Inc.
QNCX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for QNCX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · QNCX
Quince Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases, currently evaluating strategic alternatives after its lead drug candidate eDSP failed to meet endpoints in a Phase 3 trial.
Key risk: Lead drug failure
BioSniper Score
Based on 5 of 6 signals
Market Cap
$34.3M
Cash Runway
18.8 moLead Asset
edsp (Phase 3)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials · 1 catalyst for Quince Therapeutics, Inc..
Quince Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases, currently evaluating strategic alternatives after its lead drug candidate eDSP failed to meet endpoints in a Phase 3 trial.
- Lead drug candidate eDSP failed to meet primary or secondary endpoints in the Phase 3 NEAT clinical trial for Ataxia-Telangiectasia (A-T) [sec_mda · as of 2026-08-14].
- Cash and equivalents of $116.0M as of 2026-06-30 [sec].
- Accumulated deficit of $500.0 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
- Net income of -$75.5M for the period ending 2026-06-30 [sec].
- Shareholders' equity of -$35.7M as of 2026-06-30 [sec].
What works
- Cash position of $116.0M as of 2026-06-30 provides a substantial buffer for evaluating strategic alternatives [sec].
- The company has a proprietary AIDE technology platform that was previously the focus of its strategic efforts [sec_mda · as of 2025-08-11].
What to weigh
- Lead drug candidate eDSP failed to meet primary or secondary endpoints in the Phase 3 NEAT trial, and development has been discontinued [sec_mda · as of 2026-08-14].
- The company has an accumulated deficit of $500.0 million as of June 30, 2026, with no product revenue expected unless marketing approval is obtained [sec_mda · as of 2026-08-14].
- Shareholders' equity is negative at -$35.7M as of 2026-06-30, indicating a net deficit position [sec].
- The company has previously disclosed substantial doubt about its ability to continue as a going concern [sec_mda · as of 2025-05-13].
From the filings
Quoted directly from source documents.
Catalyst timeline
- 2026-12-31 · Phase2_Topline · lam-001 — Phase 2 Readout: lam-001 — Topline data from the Phase 2 trial of lam-001 will be reported, which may inform the company's future direction.
Risks & what to watch (4)›
Key risks
- Lead drug failure — eDSP failed Phase 3 endpoints; development discontinued, leaving no active pipeline candidate [sec_mda · as of 2026-08-14].
- Going concern uncertainty
- Negative shareholders' equity — Shareholders' equity of -$35.7M as of 2026-06-30 indicates liabilities exceed assets [sec].
- No product revenue — No product revenue expected unless marketing approval is obtained, which is uncertain [sec_mda · as of 2026-08-14].
What to watch
- Phase 2 topline readout for lam-001 expected on 2026-12-31 [catalyst].
- Any announcement of strategic alternatives, including potential reverse merger or asset sale [sec_mda · as of 2026-05-11].
- Cash burn rate and any additional financing activities given the negative equity position [sec].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Quince Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Quince Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
18.8 months
OCF -$19M · Net income -$75M
Lead: Phase 3
2 candidates
1 upcoming, next in ~123d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$26K
| Holder | Shares | Value |
|---|---|---|
| tudor investment corp et al | 220,000 | $22K |
| gen-wealth partners inc | 33,018 | $3K |
Short Interest
as of Apr 21, 2026- % of float
- 27.7%
- Days to cover
- 0.4
- Shares short
- 1,382,655
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
QNCX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Quince Therapeutics, Inc.?
Quince Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases, currently evaluating strategic alternatives after its lead drug candidate eDSP failed to meet endpoints in a Phase 3 trial.
What is Quince Therapeutics, Inc.'s lead drug candidate?
Quince Therapeutics, Inc.'s most advanced tracked candidate is edsp (Phase 3) for Duchenne muscular dystrophy (DMD).
What is Quince Therapeutics, Inc.'s next catalyst?
Quince Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: lam-001" — expected December 31, 2026.
Who is the CEO of Quince Therapeutics, Inc.?
Dr. Dirk Thye M.D. is the chief executive officer of Quince Therapeutics, Inc. (QNCX).
Where is Quince Therapeutics, Inc. headquartered?
Quince Therapeutics, Inc. (QNCX) is headquartered in South San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.